+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Central Nervous System Drugs Market Global Briefing 2018

  • ID: 4452390
  • Report
  • Region: Global
  • 35 pages
  • The Business Research Company
1 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd.
  • Limited
  • Pfizer Inc.
  • Shire Plc.
  • MORE
The global central nervous system drugs market is expected to reach around $82 billion in 2020. Going forward, the growth of this market can be attributed to steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions.

Central Nervous System Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs sector.

Reasons to Purchase:
  • Fully updated for 2018.
  • Identify growth segments and opportunities.
  • Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
  • Develop strategies based on likely future developments.
  • Gain a global perspective on the development of the market.
Description

Central Nervous System Drugs Market Global Briefing 2018 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the central nervous system drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the central nervous system drugs market and suggests approaches.

Scope:

Markets Covered: Anaesthetics, Analgesics, Anti-Parkinson drugs, Anti-Epileptics, Other CNS drugs.
Companies Mentioned: Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc., Novartis AG, Shire Plc., UCB S.A., Eli Lilly and Company, Sanofi S.A., Daiichi Sankyo Company Limited
Geographic Scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa
Time Series: Five years historic and forecast.
Data: Market value in $ billions.
Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd.
  • Limited
  • Pfizer Inc.
  • Shire Plc.
  • MORE
Central Nervous System Drugs Market Characteristics
Central Nervous System Drugs Market Historic Growth (2013 - 2017)
Central Nervous System Drugs Market Forecast Growth (2017 - 2021)
Central Nervous System Drugs Market Segmentation
Global Central Nervous System Drugs Market, Split by Segments, 2017, $ Billion
Anaesthetics
Analgesics
Anti-Parkinson drugs
Anti-Epileptics
Other CNS drugs
Global Central Nervous System Drugs Market, Historic and Forecast, Split by Segments, 2013 - 2021
Central Nervous System Drugs Market Geography Regional and Country Comparison
Global Central Nervous System Drugs Market, Split by Regions, 2017
Global Central Nervous System Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Global Central Nervous System Drugs Market, Split by Country, 2017
Global Central Nervous System Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Central Nervous System Drugs Market Competitive Landscape
Biogen Inc
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Pfizer Inc
Novartis AG
Shire Plc
UCB S.A
Eli Lilly and Company
Sanofi S.A
Daiichi Sankyo Company, Limited
Biogen Idec
F.Hoffmann-La Roche
Johnson & Johnson (J&J)
Central Nervous System Drugs Market Key Mergers and Acquisitions
Teva Acquired Auspex Pharmaceuticals
Pfizer Acquired Bamboo Therapeutics
Sunovion Acquired Cynapsus Therapeutics
Novartis Acquired Spinifex Pharmaceuticals
Otsuka Acquired Neurovance
Biogen Acquired Rodin Therapeutics
Central Nervous System Drugs Market Trends and Strategies
Wearables To Improve R&D
Biomarkers in CNS Drug Development
Regenerative Therapies For Central Nervous System Diseases
Appendix
NAICS Definitions of Industry Covered in This Report
Definition of Market Covered in This Report
Abbreviations
Currencies
Research Methodology
Research Inquiries
About the Publisher

List of Figures
Figure 1: Global Central Nervous System Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Figure 2: Global Central Nervous System Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Figure 3: Global Central Nervous System Drugs Market, Split by Segments, 2017, $ Billion
Figure 4: Global Central Nervous System Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Figure 5: Global Central Nervous System Drugs Market, Split by Region, 2017, $ Billion
Figure 6: Global Central Nervous System Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Figure 7: Global Central Nervous System Drugs Market, Split by Country, 2017, $ Billion
Figure 8: Global Central Nervous System Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Figure 9: Global Central Nervous System Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)

List of Tables
Table 1: Global Central Nervous System Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Table 2: Global Central Nervous System Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Table 3: Global Central Nervous System Drugs Market, Split by Segments, 2017, $ Billion
Table 4: Global Central Nervous System Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Table 5: Global Central Nervous System Drugs Market, Split by Region, 2017, $ Billion
Table 6: Global Central Nervous System Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Table 7: Global Central Nervous System Drugs Market, Split by Country, 2017, $ Billion
Table 8: Global Central Nervous System Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Table 9: Global Central Nervous System Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd.
  • Limited
  • Pfizer Inc.
  • Shire Plc.
  • MORE
The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body.

North America was the largest region in the central nervous system drugs market in 2017, accounting for around 37% market share. This can be attributed to high per capita spending on drugs to treat central nervous system disorders, the aging population and the insurance system which supports high healthcare costs in the USA. Western Europe was the second largest region accounting for around 20% market share. Asia Pacific was the third largest region accounting for around 19% market share.

Wearables to Improve R&D - Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. for instance, in 2016, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.
Note: Product cover images may vary from those shown
5 of 4
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Shire Plc.
  • UCB S.A.
  • Eli Lilly
  • Company
  • Sanofi S.A.
  • Daiichi Sankyo Company
  • Limited
Note: Product cover images may vary from those shown
Adroll
adroll